ArticleEcancermedicalscience2017

Responsible pricing in value-based assessment of cancer drugs: real-world data are an inevitable addition to select meaningful new cancer treatments.

Wim van Harten et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.